immunePCS
immunePCS LLC provides preclinical consulting services to help biotechnology and pharmaceutical companies navigate the drug discovery and development pipeline, especially in immuno-oncology. With over 30 years of experience, they support all preclinical phases for small molecules and biologics, offering expertise in study design, model selection, and toxicology. They also assist in business development, commercialization, marketing, and communication strategies to ensure successful drug development and market entry.
Industries
Nr. of Employees
small (1-50)
immunePCS
Boston, Massachusetts, United States, North America
Services
Consulting services covering early discovery through preclinical development for small molecules and biologics, including study design, model selection, HTS/assay guidance, PK/PD optimization, and toxicology planning to support IND filing.
Guidance on commercialization planning, intellectual property strategy, assembling scientific/business teams, CRO selection, due diligence, and negotiation support.
Preparation of grant proposals, scientific manuscripts, conference materials, investor pitches, webinars, and regulatory protocol documents.
Consulting services covering early discovery through preclinical development for small molecules and biologics, including study design, model selection, HTS/assay guidance, PK/PD optimization, and toxicology planning to support IND filing.
Guidance on commercialization planning, intellectual property strategy, assembling scientific/business teams, CRO selection, due diligence, and negotiation support.
Preparation of grant proposals, scientific manuscripts, conference materials, investor pitches, webinars, and regulatory protocol documents.
Expertise Areas
- Preclinical development and IND readiness
- Immuno-oncology and translational medicine
- Toxicology and safety assessment (GLP/non-GLP)
- PK/PD study design and analysis
Key Technologies
- In vivo animal models for oncology
- High-throughput screening (HTS) assays
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling
- GLP and non-GLP toxicology studies